BACKGROUND: Despite a paucity of evidence, decolonization measures are prescribed for outpatients with recurrent Staphylococcus aureus skin and soft-tissue infection (SSTI). OBJECTIVE: Compare the effectiveness of 4 regimens for eradicating S. aureus carriage. DESIGN: Open-label, randomized controlled trial. Colonization status and recurrent SSTI were ascertained at 1 and 4 months. SETTING: Barnes-Jewish and St. Louis Children's Hospitals, St. Louis, Missouri, 2007-2009. PARTICIPANTS: Three hundred patients with community-onset SSTI and S. aureus colonization in the nares, axilla, or inguinal folds. INTERVENTIONS: Participants were randomized to receive no therapeutic intervention (control subjects) or one of three 5-day regimens: 2% mupirocin ointment applied to the nares twice daily, intranasal mupirocin plus daily 4% chlorhexidine body washes, or intranasal mupirocin plus daily dilute bleach water baths. RESULTS: Among 244 participants with 1-month colonization data, modified intention-to-treat analysis revealed S. aureus eradication in 38% of participants in the education only (control) group, 56% of those in the mupirocin group (P = .03 vs controls), 55% of those in the mupirocin and chlorhexidine group (P = .05), and 63% off those in the mupirocin and bleach group (P = .006). Of 229 participants with 4-month colonization data, eradication rates were 48% in the control group, 56% in the mupirocin only group (P = .40 vs controls), 54% in the mupirocin and chlorhexidine group (P = .51), and 71% in the mupirocin and bleach group (P = .02). At 1 and 4 months, recurrent SSTIs were reported by 20% and 36% of participants, respectively. CONCLUSIONS: An inexpensive regimen of dilute bleach baths, intranasal mupirocin, and hygiene education effectively eradicated S. aureus over a 4-month period. High rates of recurrent SSTI suggest that factors other than endogenous colonization are important determinants of infection. Trial registration. ClinicalTrials.gov identifier: NCT00513799.
RCT Entities:
BACKGROUND: Despite a paucity of evidence, decolonization measures are prescribed for outpatients with recurrent Staphylococcus aureus skin and soft-tissue infection (SSTI). OBJECTIVE: Compare the effectiveness of 4 regimens for eradicating S. aureus carriage. DESIGN: Open-label, randomized controlled trial. Colonization status and recurrent SSTI were ascertained at 1 and 4 months. SETTING: Barnes-Jewish and St. Louis Children's Hospitals, St. Louis, Missouri, 2007-2009. PARTICIPANTS: Three hundred patients with community-onset SSTI and S. aureus colonization in the nares, axilla, or inguinal folds. INTERVENTIONS:Participants were randomized to receive no therapeutic intervention (control subjects) or one of three 5-day regimens: 2% mupirocin ointment applied to the nares twice daily, intranasal mupirocin plus daily 4% chlorhexidine body washes, or intranasal mupirocin plus daily dilute bleachwater baths. RESULTS: Among 244 participants with 1-month colonization data, modified intention-to-treat analysis revealed S. aureus eradication in 38% of participants in the education only (control) group, 56% of those in the mupirocin group (P = .03 vs controls), 55% of those in the mupirocin and chlorhexidine group (P = .05), and 63% off those in the mupirocin and bleach group (P = .006). Of 229 participants with 4-month colonization data, eradication rates were 48% in the control group, 56% in the mupirocin only group (P = .40 vs controls), 54% in the mupirocin and chlorhexidine group (P = .51), and 71% in the mupirocin and bleach group (P = .02). At 1 and 4 months, recurrent SSTIs were reported by 20% and 36% of participants, respectively. CONCLUSIONS: An inexpensive regimen of dilute bleach baths, intranasal mupirocin, and hygiene education effectively eradicated S. aureus over a 4-month period. High rates of recurrent SSTI suggest that factors other than endogenous colonization are important determinants of infection. Trial registration. ClinicalTrials.gov identifier: NCT00513799.
Authors: Timothy F Jones; C Buddy Creech; Paul Erwin; Susan G Baird; Amy M Woron; William Schaffner Journal: Clin Infect Dis Date: 2006-03-30 Impact factor: 9.079
Authors: Richard V Goering; Linda K McDougal; Greg E Fosheim; Kristin K Bonnstetter; Daniel J Wolter; Fred C Tenover Journal: J Clin Microbiol Date: 2007-04-04 Impact factor: 5.948
Authors: Andrew E Simor; Elizabeth Phillips; Allison McGeer; Ana Konvalinka; Mark Loeb; H Rosalyn Devlin; Alex Kiss Journal: Clin Infect Dis Date: 2006-12-14 Impact factor: 9.079
Authors: Sheldon L Kaplan; Kristina G Hulten; Blanca E Gonzalez; Wendy A Hammerman; Linda Lamberth; James Versalovic; Edward O Mason Journal: Clin Infect Dis Date: 2005-05-06 Impact factor: 9.079
Authors: Susan C Bleasdale; William E Trick; Ines M Gonzalez; Rosie D Lyles; Mary K Hayden; Robert A Weinstein Journal: Arch Intern Med Date: 2007-10-22
Authors: Michael W Ellis; Matthew E Griffith; David P Dooley; Joseph C McLean; James H Jorgensen; Jan E Patterson; Kepler A Davis; Joshua S Hawley; Jason A Regules; Robert G Rivard; Paula J Gray; Julia M Ceremuga; Mary A Dejoseph; Duane R Hospenthal Journal: Antimicrob Agents Chemother Date: 2007-08-06 Impact factor: 5.191
Authors: C Wendt; S Schinke; M Württemberger; K Oberdorfer; O Bock-Hensley; H von Baum Journal: Infect Control Hosp Epidemiol Date: 2007-07-03 Impact factor: 3.254
Authors: Duha Al-Zubeidi; Carey-Ann D Burnham; Patrick G Hogan; Rachel Collins; David A Hunstad; Stephanie A Fritz Journal: J Pediatric Infect Dis Soc Date: 2013-07-30 Impact factor: 3.164
Authors: Michael W Ellis; Carey D Schlett; Eugene V Millar; Kenneth J Wilkins; Katrina B Crawford; Stephanie M Morrison-Rodriguez; Laura A Pacha; Rachel J Gorwitz; Jeffrey B Lanier; David R Tribble Journal: Clin Infect Dis Date: 2014-03-14 Impact factor: 9.079
Authors: C A Burnham; Patrick G Hogan; Meghan A Wallace; Elena Deych; William Shannon; David K Warren; Stephanie A Fritz Journal: Antimicrob Agents Chemother Date: 2016-11-21 Impact factor: 5.191
Authors: Stephanie A Fritz; Kristin M Tiemann; Patrick G Hogan; Emma K Epplin; Marcela Rodriguez; Duha N Al-Zubeidi; Juliane Bubeck Wardenburg; David A Hunstad Journal: Clin Infect Dis Date: 2013-02-27 Impact factor: 9.079